FDA Wants Clinically Meaningful Outcomes, Mortality Measured in IPF Trials

Clinical trials for idiopathic pulmonary fibrosis should emphasize efficacy outcomes that are clinically meaningful to patients, and should measure mortality as a means of validating the endpoints chosen, an FDA official said, but exactly what those endpoints are is still uncertain